Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
S2409
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- NCT06769126 ↗
- Recruiting
- SWOG Cancer Research Network
- Standard
We haven't built an HCP commentary report on S2409 (ceralasertib, durvalumab and 4 more in Extensive Stage Lung Small Cell Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on S2409 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 7 | |
| X threads | 5 | |
| Podcasts | 3 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype; Lung Small Cell Carcinoma, I Subtype; Lung Small Cell Carcinoma, N Subtype; Lung Small Cell Carcinoma, P Subtype
- Interventions
- Biospecimen Collection; Ceralasertib; Computed Tomography; Durvalumab; Etoposide; Magnetic Resonance Imaging; Monalizumab; Platinum Compound; Positron Emission Tomography; Saruparib; Thoracic Radiation Therapy
- Arms
- Cohort A, Arm 1 (durvalumab) · Experimental
- Cohort A, Arm 2 (durvalumab, saruparib) · Experimental
- Cohort B, Arm 1 (durvalumab) · Experimental
- Cohort B, Arm 2 (durvalumab, ceralasertib) · Experimental
- Cohort C, Arm 1 (durvalumab) · Experimental
- Cohort C, Arm 2 (durvalumab, monalizumab) · Experimental
- Enrollment
- 900 (estimated)
- Primary outcomes
- Screen success rate (Screening)
- Progression-free survival (PFS) (Cohort A)
- PFS (Cohort B)
- PFS (Cohort C)
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Nov 6, 2025
- Primary completion
- Dec 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06769126 · updated Mar 30, 2026